1. US FDA. Dojolvi™ (triheptanoin) oral liquid: US prescribing information. 2020. http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213687s000lbl.pdf. Accessed 31 Jul 2020.
2. Ultragenyx Pharmaceutical. Ultragenyx announces U.S. FDA approval of Dojolvi™ (UX007/triheptanoin), the first FDA-approved therapy for the treatment of long-chain fatty acid oxidation disorders [media release]. 2020. https://www.ultragenyx.com. Accessed 31 Jul 2020.
3. US FDA. Dojolvi (triheptanoin) oral liquid: NDA approval. 2020. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213687Orig1s000replacementltr.pdf. Accessed 31 Jul 2020.
4. Merritt JL, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann of Transl Med. 2018;6(24):473.
5. Gillingham MB, Heitner SB, Martin J, et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017;40(6):831–43.